Palvella Therapeutics, Inc. (NASDAQ:PVLA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Palvella Therapeutics, Inc. (NASDAQ:PVLA) has been assigned an average recommendation of “Moderate Buy” from the fifteen brokerages that are presently covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $198.0714.

PVLA has been the subject of a number of research reports. Wall Street Zen downgraded Palvella Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, April 11th. Truist Financial set a $210.00 price target on Palvella Therapeutics in a research report on Tuesday, February 24th. HC Wainwright boosted their price target on Palvella Therapeutics from $255.00 to $270.00 and gave the company a “buy” rating in a research report on Tuesday, March 24th. Mizuho increased their price target on Palvella Therapeutics from $205.00 to $250.00 and gave the company an “outperform” rating in a report on Wednesday, February 25th. Finally, BTIG Research increased their price target on Palvella Therapeutics from $192.00 to $215.00 and gave the company a “buy” rating in a report on Wednesday, February 25th.

Palvella Therapeutics Trading Down 2.1%

PVLA stock opened at $125.96 on Wednesday. The stock has a 50-day moving average price of $122.90 and a two-hundred day moving average price of $100.66. Palvella Therapeutics has a 12-month low of $20.20 and a 12-month high of $151.18. The company has a market cap of $1.80 billion, a PE ratio of -33.95 and a beta of -0.21.

Palvella Therapeutics (NASDAQ:PVLA) last posted its quarterly earnings results on Tuesday, March 31st. The company reported ($1.08) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.13). Equities analysts forecast that Palvella Therapeutics will post -4.87 EPS for the current fiscal year.

Insider Activity at Palvella Therapeutics

In related news, Director Elaine J. Heron purchased 2,400 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was purchased at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the acquisition, the director owned 47,812 shares in the company, valued at approximately $5,976,500. This trade represents a 5.28% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Kathleen Goin sold 4,302 shares of the stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total value of $507,592.98. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is owned by insiders.

Institutional Trading of Palvella Therapeutics

Several large investors have recently added to or reduced their stakes in the stock. Keybank National Association OH acquired a new stake in Palvella Therapeutics in the 1st quarter valued at $228,000. Invesco Ltd. increased its holdings in Palvella Therapeutics by 11.6% in the 4th quarter. Invesco Ltd. now owns 54,273 shares of the company’s stock valued at $5,681,000 after purchasing an additional 5,663 shares in the last quarter. XTX Topco Ltd acquired a new stake in Palvella Therapeutics in the 4th quarter valued at $429,000. Virtus Investment Advisers LLC acquired a new stake in Palvella Therapeutics in the 4th quarter valued at $282,000. Finally, Superstring Capital Management LP purchased a new position in Palvella Therapeutics in the 4th quarter valued at about $2,666,000. 40.11% of the stock is currently owned by institutional investors and hedge funds.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.